OnKure Therapeutics, Inc. financial data

Symbol
OKUR on Nasdaq
Location
Boulder, CO
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 06 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1108% % -40%
Debt-to-equity 10% %
Return On Equity -75% % -628%
Return On Assets -68% % -181%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33,428,808 shares -1.1%
Common Stock, Shares, Outstanding 3,343,525 shares -90%
Entity Public Float $27,700,000 USD -82%
Common Stock, Value, Issued $0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 13,530,892 shares 4180%
Weighted Average Number of Shares Outstanding, Diluted 13,530,892 shares 4180%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $51,901,000 USD 130%
General and Administrative Expense $15,624,000 USD 157%
Operating Income (Loss) $67,525,000 USD -363%
Net Income (Loss) Attributable to Parent $63,456,000 USD -280%
Earnings Per Share, Basic 93 USD/shares 97%
Earnings Per Share, Diluted 93 USD/shares 97%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $70,331,000 USD 16%
Cash, Cash Equivalents, and Short-term Investments $76,700,000 USD
Assets, Current $71,526,000 USD -7.1%
Property, Plant and Equipment, Net $720,000 USD 1120%
Operating Lease, Right-of-Use Asset $485,000 USD 10%
Other Assets, Noncurrent $104,000 USD -29%
Assets $72,835,000 USD -6.2%
Accounts Payable, Current $1,290,000 USD 444%
Employee-related Liabilities, Current $2,978,000 USD
Accrued Liabilities, Current $4,660,000 USD 389%
Liabilities, Current $6,247,000 USD 92%
Operating Lease, Liability, Noncurrent $120,000 USD -68%
Other Liabilities, Noncurrent $40,000 USD
Liabilities $6,407,000 USD 77%
Accumulated Other Comprehensive Income (Loss), Net of Tax $2,000 USD
Retained Earnings (Accumulated Deficit) $200,738,000 USD 15%
Stockholders' Equity Attributable to Parent $66,428,000 USD
Liabilities and Equity $72,835,000 USD -6.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,005,000 USD -32%
Net Cash Provided by (Used in) Financing Activities $77,000 USD -870%
Net Cash Provided by (Used in) Investing Activities $18,000 USD
Common Stock, Shares Authorized 210,000,000 shares 5%
Common Stock, Shares, Issued 3,343,525 shares -90%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $14,100,000 USD -33%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $70,331,000 USD 784%
Deferred Tax Assets, Valuation Allowance $90,855,000 USD 309%
Deferred Tax Assets, Gross $90,855,000 USD 309%
Operating Lease, Liability $687,000 USD 3.3%
Payments to Acquire Property, Plant, and Equipment $18,000 USD 100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $41,010,000 USD 39%
Lessee, Operating Lease, Liability, to be Paid $705,000 USD -6.5%
Property, Plant and Equipment, Gross $2,080,000 USD
Operating Lease, Liability, Current $567,000 USD 98%
Lessee, Operating Lease, Liability, to be Paid, Year Two $560,000 USD 53%
Lessee, Operating Lease, Liability, to be Paid, Year One $560,000 USD 51%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $18,000 USD -80%
Deferred Tax Assets, Operating Loss Carryforwards $53,984,000 USD 498%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares
Unrecognized Tax Benefits $0 USD
Operating Lease, Payments $140,000 USD 164%
Additional Paid in Capital $267,165,000 USD -14%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $459,000 USD -5.3%
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $11,147,000 USD 3745%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares